BEAM
Beam Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website beamtx.com
- Employees(FY) 439
- ISIN US07373V1052
Performance
-12.35%
1W
+3.55%
1M
-2.04%
3M
-0.53%
6M
-10.03%
YTD
-20.38%
1Y
Profile
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Technical Analysis of BEAM 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-12 16:01
- 2024-11-12 03:01
- 2024-11-08 16:23
- 2024-11-07 06:26
- 2024-11-06 14:26
- 2024-11-06 11:37
- 2024-11-06 10:34
- 2024-11-06 07:45
- 2024-11-06 06:39
- 2024-11-06 02:12
- 2024-11-06 01:40
Q3 2024 Beam Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-11-05 15:37
- 2024-11-05 09:11
Beam Therapeutics' Q3 Net Loss Narrows, Revenue Falls(MT Newswires)
- 2024-11-05 09:00
- 2024-11-05 07:40
- 2024-11-05 06:30
- 2024-11-04 20:00
- 2024-11-04 17:30
- 2024-11-04 15:18
- 2024-10-31 03:50
- 2024-10-30 08:40
- 2024-10-29 06:30
- 2024-10-28 18:30
- 2024-10-28 07:46
- 2024-10-22 20:47
- 2024-10-17 15:05
- 2024-10-16 16:47
- 2024-10-16 08:22
- 2024-09-18 07:14
JonesTrading Initiates Beam Therapeutics at Hold(MT Newswires)
- 2024-09-05 11:31
Page 1 of 8
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.